AUTEL
17.1.2023 12:58:40 CET | Business Wire | Press release
Autel is today announcing the launch of an innovative electric vehicle DC charger, the MaxiCharger DC Compact, providing up to 40kW of DC power for the U.S. version and 47kW of power for the European version. The MaxiCharger DC Compact comes with two charging cables, allowing two vehicles to charge simultaneously with dynamic power distribution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117005624/en/
The MaxiCharger DC Compact comes with options like a credit card reader and a pedestal. (Photo: Business Wire)
The MaxiCharger DC Compact is sleek and compact with a 21.5-inch LCD touchscreen for user-friendly interaction and advertising capability. It can be hung on a wall, placed on a pedestal, or set on wheels for ultimate portability. The MaxiCharger DC Compact is perfect for businesses wanting to provide their customers with a quick top-up charge option without breaking the bank on a DC Fast charger. It is also an excellent option for commercial fleets that need a slower DC charge for their fleet vehicles to charge overnight.
“This is an exciting launch for Autel as we establish ourselves as the worldwide leader in electric vehicle charging,” said Kelvin Cao, Vice President of Global Marketing at Autel. “The MaxiCharger DC Compact is small in size but a powerful addition to our growing portfolio of EV chargers, and a great fit for businesses needing an affordable, yet fast EV charger.”
Elevated Efficiency with Dual Ports
The MaxiCharger DC Compact is designed to increase charging efficiency, providing up to 47kW of power with dual-ports. It can charge 2 vehicles simultaneously, sharing power dynamically between the two vehicles. A 30 minute charge equates to about 130 km of range, saving on charging time.
Smart Advertising and Communication Platform
Powered by the smart operating system, Android 10, with a user-friendly 21.5-inch LCD touchscreen and enhanced advertising placement capability, the MaxiCharger DC Compact communicates with, engages and attracts customers, generating new revenue streams.
Compatibility
The MaxiCharger DC Compact is OCPP1.6 capable. It is compatible with CCS1, CCS2 and CHAdeMO charging cables, depending on operator and regional needs. With the Autel Charge app, RFID cards, and credit card capability, the MaxiCharger DC Compact offers convenient ways for end users to pay for and begin their charging sessions. It offers 4G, Wi-Fi, and ethernet connectivity options and supports regular over-the-air software updates with an internet connection.
Cloud Platform
The MaxiCharger DC Compact is powered on the backend using Autel’s smart charge cloud platform. The cloud platform helps charge point operators view, monitor, and analyze charger data in real-time. Operators can also view revenue and user data, and set advertisements all from the cloud platform. Autel’s cloud management platform allows all operators to efficiently and conveniently manage their chargers in one easy-to-use interface.
Become a Dealer
If you are interested in becoming a dealer for the MaxiCharger DC Compact and for all of the MaxiCharger series of EV chargers, head over to the Autel website and fill out our dealer form. If you are interested in purchasing a MaxiCharger DC Compact, contact your local Autel sales representative or contact us below.
About Autel
Autel designs, engineers, and manufactures some of the most advanced products for residential and commercial users, offering hardware, software, apps, and cloud-based solutions to cover almost every use case and application.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005624/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom